Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and ESHAP in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00367497Phase 2Terminated
- Sponsor
- Keio University
- Start
- Aug 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in non-Hodgkin lymphoma (NHL), sponsored by Keio University. Primary endpoint: Overall Response Rate. Started Aug 2005; status: terminated.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00367497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367497.